Erin E. Congdon

This study evaluates five anti-α-synuclein single-domain antibodies in Drosophila models, identifying 2H1 as the most effective in reducing pathology and improving disease parameters.

The paper compares pSer396- and pSer404-selective antibodies, showing differences in efficacy and structural binding modes, and highlights how humanization affects their therapeutic properties.

This study shows that targeting truncated tau protein with a monoclonal antibody reduces tau levels, improves neuronal function, and decreases microglia activation in tauopathy mouse models.

This paper presents a single-domain antibody-based protein degrader that reduces tau levels and improves motor function in tauopathy models.

This paper develops a single-domain antibody-based protein degrader that enhances proteasomal and lysosomal degradation of α-synuclein in synucleinopathy models.